MedPath

Pharmaceutical Care of Patients With Impaired Mobility in a Model-region of Decreasing Supply of Medical Services

Phase 4
Conditions
Diabetes
Interventions
Behavioral: counseling
Registration Number
NCT01587599
Lead Sponsor
Foerderinitiative Pharmazeutische Betreuung e.V.
Brief Summary

Design and Procedure:

The design is a randomised controlled multi-centre pilot study. 18 community pharmacies located in Mecklenburg-Western Pomerania, Germany, were randomised to either a control or an intervention group. These pharmacies recruited eligible patients out of their clientele and invited them to take part in the study. Participants were visited at home by the pharmacist and home-based medication reviews were conducted. The survey form has been developed by the research team and comprised amongst others items to adherence, adverse effects, drug intake, storage and quality of life. Thereafter all data were analysed by the pharmacist with a newly developed document called "analysis guide" aiming at the detection of drug related problems. Pharmacists of the intervention group discussed the results with the family doctor of the patients and the patients and tried to solve the drug related problems. This procedure was not undertaken in the control group.

Six months later a second medication review was carried out in both groups.

Study hypothesis:

Pharmaceutical care reduces the overall number of drug-related problems of elderly patients with diabetes and impairments in mobility.

Aim:

The purpose of this study is to show that pharmaceutical care reduces the overall number of drug-related problems of elderly diabetes-patients with impairments in mobility and leads to both an improved health status and an improved quality of life.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
54
Inclusion Criteria
  • impairment in mobility
  • age of 65 years or older
  • four or more long-term medications
  • diabetes
  • at least one of the following co-morbidities: hypertension, obesity, hypercholesteremia, hyperlipidemia, coronary heart disease, cardiac insufficiency, angina pectoris, peripheral vascular disease
Exclusion Criteria
  • patient lives in a home for the aged or a residential care home for the elderly
  • terminal renal failure, dialysis
  • moderately or severe dementia or other severe cognitive impairments
  • terminal diseases (e.g. cancer)
  • nursing service if the medicine is directly administered to the patient

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Pharmaceutical carecounseling-
Standard carecounseling-
Primary Outcome Measures
NameTimeMethod
adherence6 months

MMAS-8d

adverse events6 months

SHIP-trend 8-items questionnaire

drug-drug-interactions6 months

ABDATA drug-drug interaction identification tool

Secondary Outcome Measures
NameTimeMethod
quality of life6 months

improvement of quality of life, measured with eq-5d

improved overall health status6 months
© Copyright 2025. All Rights Reserved by MedPath